Previous 10 | Next 10 |
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Steve E. Krognes to its board of directors. Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at De...
Which of the healthcare producers of Diagnostic Solutions is now a better buy to help build your portfolio’s near-term capital value? Near-term only, repetition provides long term. Here find out what the best-informed, big-$ investors now think is likely to happen (good and bad...
Gainers:Scholar Rock Holding (SRRK) +6%. Science 37 Holdings (SNCE) +6%. Arcimoto (FUV) +5%. Hyzon Motors (HYZN) +4%. SoundHound (SOUN) +4%. Losers: Guardant Health (GH) -5%. CymaBay Therapeutics (CBAY) -5%. Polestar Automotive Holding (PSNY) -5%. Adagio Therapeutics, (...
The following slide deck was published by Guardant Health, Inc. in conjunction with this event. For further details see: Guardant Health (GH) Presents at the William Blair 42nd Annual Growth Stock Conference - Slideshow
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Middle East and Africa ...
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...
Guardant Health (NASDAQ: GH) , a diagnostic precision oncology testing company, saw its shares plummet 33.6% in May, according to data from S&P Global Market Intelligence . The stock closed at $61.70 a share on April 29, the last trading day of the month. It opened at $...
Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient ...
Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron...
Oral presentation in Clinical Science Symposium will demonstrate use of real-world data from GuardantINFORM to identify resistance to early treatment in advanced breast cancer Oral presentation in Breast Cancer-Metastatic Session will highlight updated progression-free survi...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...